BHV3000-302 : Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
Phase of Trial: Phase III
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Sponsors Biohaven Pharmaceutical Holding Company
- 19 Apr 2018 According to a Biohaven Pharmaceutical Holding Company media release, based on the results of BHV3000-301 and BHV3000-302 trials, the company plans for the submission of a NDA to the FDA in 2019.
- 19 Apr 2018 According to a Biohaven Pharmaceutical Holding Company media release, data from this study will be present at the 2018 American Academy of Neurology (AAN) Annual Meeting. Also, the company plans to release this data at an Investor event.
- 26 Mar 2018 Results presented in a Biohaven Pharmaceutical Holding Company media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History